Trials / Completed
CompletedNCT03254914
Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
A Multi-center, Cluster-randomized, Prospective, Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,554 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or more concomitant antihypertensive agents including fimasartan
Detailed description
A multi-center, cluster-randomized, prospective, observational study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Home Blood Pressure | Measure Home Blood Pressure |
Timeline
- Start date
- 2017-08-09
- Primary completion
- 2018-10-31
- Completion
- 2019-02-28
- First posted
- 2017-08-21
- Last updated
- 2024-12-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03254914. Inclusion in this directory is not an endorsement.